Evidence map›Paper›PMID 40826336›Full record

Trial reportBMC infectious diseases2025

Efficacy of two brands of Mebendazole (500 mg) in the treatment of Ascaris lumbricoides and hookworm infection among school-aged children in South Gondar zone, Northwest Ethiopia: a randomized open label trial.

Birhanu Malede, Ayalew Jejaw Zeleke, Yenesew Mihret Wondmagegn, Abebaw Setegn, Hailegebriel Wondimu, Ayenew Berhan, Tadesse Misganaw, Gashaw Azanaw Amare, Tegegne Eshetu

Abstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Birhanu MaledeDepartment of Medical Laboratory, College of Medicine and Health Science, Debre Markos University, Debre Markos, Ethiopia. birhanu3rd@gmail.com.
Ayalew Jejaw ZelekeDepartment of Medical Parasitology, School of Biomedical and Laboratory science, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Yenesew Mihret WondmagegnDepartment of Medical Parasitology, School of Biomedical and Laboratory science, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Abebaw SetegnDepartment of Medical Parasitology, School of Biomedical and Laboratory science, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Hailegebriel WondimuDepartments of Medical Laboratory, Debre Tabor Health Science College, Debre Tabor, Ethiopia.
Ayenew BerhanDepartment of Medical Laboratory, College of Medicine and Health Science, Debre Tabor University, Debre Tabor, Ethiopia.
Tadesse MisganawDepartment of Medical Laboratory, College of Medicine and Health Science, Woldia University, Woldia, Ethiopia.
Gashaw Azanaw AmareDepartment of Medical Laboratory, College of Medicine and Health Science, Debre Markos University, Debre Markos, Ethiopia.
Tegegne EshetuDepartment of Medical Parasitology, School of Biomedical and Laboratory science, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParasitic worms remain a serious public health problem in developing countries. Mebendazole is a widely used anthelmintic, but variations in drug efficacy among different brands of mebendazole may impact treatment outcomes. This trial investigated efficacy of two different brands of mebendazole (Vermox

methodsA randomized, open label trial was conducted among 212 children in Alember and Addis Zemen primary schools. Convenient sampling technique was used to select schools and study participants. McMaster egg counting technique was used to determine the intensity of infection. Eligible Ascaris lumbricoides or hookworm infected study participants were randomized into either a single dose of 500 mg Vermox

resultsA total of 212 school-aged children participated in the study, of which 106 school-aged children were infected by Ascaris lumbricoides and the remaining 106 were infected by hookworm parasites. From each Ascaris lumbricoides and hookworm infection group 53 school-aged children received Vermox CONCLUSION AND RECOMMENDATION: The efficacy of both brands of mebendazole against Ascaris lumbricoides and hookworm infections showed a satisfactory level based on the egg reduction rate. However, the cure rates against hookworm remains questionable, despite all study participants having light-intensity infections, which are generally expected to respond well to treatment. Further investigation is needed to evaluate the therapeutic outcomes of mebendazole in cases of moderate and heavy infection intensity to generate stronger evidence. TRIAL REGISTRY: This trial was retrospectively registered on https://pactr.samrc.ac.za/ and the unique identification number for registry was PACTR202503808932606 and the registration date was 27 March 2025.

Indexed as

AnthelminticsAscariasisAscaris lumbricoidesHookworm InfectionsMebendazoleAdolescentAncylostomatoideaAnimalsAntinematodal AgentsChildEthiopiaFecesFemaleHumansMaleParasite Egg CountAnthelminticsAntinematodal AgentsMebendazoleEfficacyMebendazoleSchool-aged childrenSoil-transmitted helminth

Identifiers

PMID40826336
PMCPMC12363100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.